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been increasingly used as a potentially valuable therapeutic intervention
in women with PMP. In a recent systematic review and meta-analysis
of 15 studies, for example, McBride et al. report mean 3-year, 5-year,
and 10-year survival rates of 77%, 76%, and 57%, respectively, in
women after various combinations of cytoreductive surgery and IPC
(McBride et al., 2013). A variant of IPC, hyperthermic intraperitoneal
chemoperfusion (HIPEC), with and without peritonectomy has also
been successfully applied to womenwith PMPwith sustained treatment
responses (Baratti et al., 2008). However, combining cytoreductive sur-
gery with IPC/HIPEC has a high morbidity and a considerable mortality.
For example, Saxena et al. reported a 3% mortality rate and grade 3 andet al., 2010). Also, the potential of IPC to improve survival in womenIntroduction
Pseudomyxoma peritonei (PMP) is a rare variant of adenocarcinoma
with a protracted but ultimately fatal course of disease. PMP has an inci-
dence of 2/1 000 000/year and is characterized by mucinous obstructive
ascites and pools of mucin within the abdominal cavity (Smeenk et al.,
2008). PMP arises from low- or high-grade mucinous neoplasms of the
appendix in N80% of cases, but ovarian involvement is common in fe-
males (Smeenk et al., 2008; Buell-Gutbrod and Gwin, 2013). The distinc-
tion between PMP from appendiceal origin and PMP from ovarian origin
is often difﬁcult (Buell-Gutbrod and Gwin, 2013), but true ovarian pri-
mary carcinoma of pure mucinous morphology presenting as PMP has
been described as a distinct clinical entity characterized by low grade
and low stage at presentation in the majority of cases (Leen and Singh,
2012). Patients with PMP usually undergo repeated surgical interven-
tions with cytoreductive surgery and removal of myxomatous masses
with or without subsequent systemic chemotherapy (Leen and Singh,
2012; Varona et al., 2005). Combination treatment modalities withnd Gynecology, Ruhr University
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. This is an open access article under4 morbidity rates of 23% and 22%, respectively, in a series of 145
women with PMP treated with cytoreductive surgery and IPC (Saxena
with PMP may be hampered by pharmacological limitations such as
poor drug distribution within the abdominal cavity and poor drug pene-
tration into peritoneal nodules (Dedrick and Flessner, 1997). Therefore,
it is reasonable to investigate less morbid and potentially more effective
IPC concepts overcoming these limitations.
One way to overcome the pharmacokinetic limitations of IPC is to
apply IPC as a pressurized aerosol taking advantage of the physical
properties of gas and pressure. This approach is based on the obser-
vation that application of chemotherapy under pressure signiﬁcantly
enhances tumor drug uptake (Dedrick and Flessner, 1997). Pressur-
ized intraperitoneal aerosol chemotherapy (PIPAC) may therefore
be a way to increase the distribution and inﬁltration depth of
intraabdominal chemotherapy. As proof of concept, PIPAC achieved
a superior distribution on the peritoneum and a better penetration
into peritoneal nodules compared to conventional IPC in an ex vivo
model (Reymond et al., 2000; Solass et al., 2012). Based on these ex-
perimental data, PIPAC has been tested in humans with recurrent
peritoneal carcinomatosis (Solass et al., 2014; Tempfer et al., 2014).
In these preliminary applications, PIPAC induced regression of peri-
toneal nodules with limited hepatic and renal toxicity. In addition,
the procedure has been shown to be safe regarding occupational
health aspects such as operation theater air contamination with
aerosol chemotherapy particles (Solass et al., 2013).
As of yet, there are no data describing PIPAC in patients with PMP.
Here we report the case of repeated successful applications of PIPACthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Intraoperative ﬁndings (macroscopy) before PIPAC therapy (panels a1, a2) and 6 weeks after PIPAC #2 (panels b1, b2). After therapy, mucus had largely disappeared from the ab-
domen, and ascites had disappeared. Nodular sclerosis of peritoneal nodules was observed, as well as reticular scarring of the visceral and the parietal peritoneum. Total peritoneal car-
cinomatosis index (PCI) remained constant, since quantitative parameters (the number and the size of tumor nodes) did not change signiﬁcantly, although the qualitative aspect of
tumor nodes was modiﬁed after therapy.
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long history of repeated surgical interventions.
Case Report
We present the case of a 62 year old womanwith PMP and a history
of repeated surgical interventions. PMPwas ﬁrst diagnosed in 2004. Ini-
tially, the patient underwent laparotomy with hysterectomy, bilateral
salpingo-oophorectomy, omentectomy, and removal of mucinous
masses. Between 2004 and 2013, laparoscopy and laparotomy were
performed 9 times with repeated tumor debulking and removal of mu-
cinous ascites. The patient presented to our clinic in January 2014 with
rising CA 125 serum levels (109 U/ml) and suspected disease progres-
sion on abdominal sonography. The patient was treated within a com-
passionate use program, approved by the ethics committee of the
Ruhr University Bochum, Bochum, Germany. The treatment was not
for research purposes.
The patient underwent three courses q 28–42 days of PIPAC with
cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 at 12 mm Hg and
37 °C for 30 min. The PIPAC procedure was performed as described be-
fore (Solass et al., 2014). Brieﬂy, after insufﬂation of a 12 mm Hg CO2
pneumoperitoneum, two balloon safety trocars (5 and 12 mm, Applied
Medical, Düsseldorf', Germany) were inserted into the abdominal wall
in an operating roomequippedwith laminar airﬂow. Video documenta-
tion was started and biopsies were taken for histologic conﬁrmation of
PMPduring theﬁrst procedure and the following procedures in order to
ascertain tumor regression. Ascites volume was documented and asci-
tes was removed. Then, a nebulizer (Reger Medizintechnik, Rottweil,
Germany) was connected to an intravenous high-pressure injector
(Injektron 82M, MedTron, Saarbruecken, Germany) and inserted into
the abdomen. The tightness of the abdomen was documented via a
zero-ﬂow of CO2. A pressurized aerosol containing cisplatin at a dose
of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% solution followed by
doxorubicin at a dose of 1.5mg/m2 body surface in a 50mlNaCl 0.9% so-
lution was applied via nebulizer and injector. The dosage used in thiscohort study was based on previous clinical experience in patients
with peritoneal carcinomatosis treated with PIPAC in this dosage and
formulation (Solass et al., 2014; Tempfer et al., 2014). Injection param-
eters were set at a ﬂow rate of 30 ml/min and a maximum upstream
pressure of 200 psi in the high-pressure injector. The injection was
remote-controlled to minimize personnel exposure. The therapeutic
capnoperitoneum was maintained for 30 min at a temperature of
37 °C. Then, the chemotherapy aerosol was exsufﬂated via a closed
line over two sequential microparticle ﬁlters into the airwaste system
of the hospital. Finally, trocars were retracted and laparoscopy was
ended. No drainage of the abdomen was applied. The PIPAC procedure
was repeated after 4–6 weeks. The peritoneal carcinomatosis index
(PCI) was determined according to Sugarbaker, based on lesion size
and distribution (Mazzei et al., 2013). Adverse events were graded ac-
cording to the Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 (Common Terminology Criteria for Adverse
Events (CTCAE)).
Fig. 1 shows snapshots of the video-laparoscopy during the ﬁrst and
third PIPACs demonstrating PMP tumor nodules. After therapy, mucus
had largely disappeared from the abdomen, and ascites had disap-
peared. The ﬁgures are snapshots taken during different PIPAC proce-
dures. Thus, the selection was subjective. We aimed to take the
snapshot pairs a1 and b1 as well as a2 and b2 from the same quadrants
(upper left and upper right, respectively), exemplifying minimization
and scarring of tumor nodules. Speciﬁcally, nodular sclerosis of perito-
neal nodules was observed, as well as reticular scarring of the visceral
and the parietal peritoneum. Objective tumor response was noted in
this patient after the third PIPAC, deﬁned as tumor regression on histol-
ogy and PCI improvement on repeated video-laparoscopy. Speciﬁcally,
major pathological tumor response with rare residual cancer cells
scattered throughout the ﬁbrosis was noted in a tissue specimen taken
during the third PIPAC. Fig. 2 demonstrates histopathological specimens
taken during PIPAC #1 and PIPAC #3 conﬁrming PMP. Before the ﬁrst
PIPAC, histology showed peritoneal inﬁltration by a poorly differentiat-
ed adenocarcinoma with extracellular mucus deposits with isolated
Fig. 2. Intraoperative ﬁndings (microscopy) before PIPAC #1 (panel a1) and 6 weeks after PIPAC #2 (panel a2) conﬁrming pseudomyxoma peritonei (PMP). Before PIPAC, histology
showed peritoneal inﬁltration by a poorly differentiated adenocarcinoma with extracellular mucus deposits with isolated tumor cells in 4/5 biopsies. After therapy, 2/3 biopsies were
tumor free, showing ﬁbrosis with acute and chronic inﬂammation. The third biopsy revealed localized peritoneal inﬁltration by a highly regressive mucinous adenocarcinoma (panel
a2, inset *).
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free, showing ﬁbrosis with acute and chronic inﬂammation. The third
biopsy revealed localized peritoneal inﬁltration by a highly regressive
mucinous adenocarcinoma. The PCI was 24 (1st PIPAC), 21 (2nd
PIPAC), and 22 (3rd PIPAC). The treatment was well tolerated. CTCAE
events grade 1 (nausea) and grade 2 (abdominal pain) were noted
within 72 h after the ﬁrst, second, and third PIPACs. No CTCAE event
grade ≥3 was observed. There was no hematologic toxicity noted on
red and white blood cell counts performed 7 days after each PIPAC.
With a follow-up of 6 months, the patient is well and alive and required
no further treatment so far. CA 125 was down to 34 U/ml.Comment
PMP is a rare disease, which is difﬁcult to treat due to its protracted
course requiring repeated interventions (Smeenk et al., 2008;
Buell-Gutbrod and Gwin, 2013). Cytoreductive surgery and IPC with
or without hyperthermia are the mainstay of treatment (McBride
et al., 2013; Saxena et al., 2010). In an effort to improve the efﬁcacy of
IPC, PIPAC has been developed and tested in experimental models
(Reymond et al., 2000; Solass et al., 2012). Preliminary data in patients
with peritoneal carcinomatosis demonstrated good tolerability and ob-
jective tumor response (Solass et al., 2014; Tempfer et al., 2014). PIPAC
can be applied repeatedly, potentially complementing cytoreductive
surgery and minimizing systemic side effects of chemotherapy. These
properties make PIPAC an attractive therapeutic tool in patients with
PMP, because repeated treatments are typically required due to the
protracted course of this disease. In addition, reducing themorbidity as-
sociated with cytoreductive surgery and IPC may be a way to improve
the quality of life of patients with PMP. We present the case of a
woman with PMP and a history of repeated surgical interventions. She
was treated with three courses q 28–42 days of PIPAC with cisplatin
7.5 mg/m2 and doxorubicin 1.5 mg/m2 at 12 mm Hg and 37 °C for
30 min. Major objective tumor response was noted, deﬁned as tumor
regression on histology and decline in CA 125. The treatment was well
tolerated. With a follow-up of 6 months, the patient is well and alive
and required no further treatment.
The choice of the cytotoxic drugs and the dosage of these drugs was
empirical, based on previous clinical experience in patientswith ovarian
cancer (Solass et al., 2014; Tempfer et al., 2014) rather than a formal
phase I dose escalation trial. A phase I trial exploring higher dosages of
PIPAC with cisplatin and doxorubicin is under way and will deﬁne themaximum tolerable dose of this combination of chemotherapeutic
agents. This trial is registered with EudraCT, number 2014-001034-28.
Based on this experience, we propose to further explore PIPAC as a
new and potential additional treatment modality in patients with
PMP. Due to the rarity of PMP, we invite colleagues to join amulticenter
effort to assess PIPAC in a prospective phase II efﬁcacy study. In summa-
ry, PIPAC is a new form of IPC, which can be applied repeatedly andmay
become a complementary or alternative treatment to repeated surgery
and IPC in patients with PMP.
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